2014-00722. Withdrawal of Approval of New Animal Drug Applications; Argent Laboratories; Formalin; Tricaine Methanesulfonate
-
Start Preamble
AGENCY:
Food and Drug Administration, HHS.
ACTION:
Notification of withdrawal.
SUMMARY:
The Food and Drug Administration (FDA) is withdrawing approval of two new animal drug applications (NADAs) held by Argent Laboratories. Withdrawal of approval of these NADAs was at the sponsor's request because the products are no longer manufactured or marketed.
DATES:
Withdrawal of approval is effective January 27, 2014.
Start Further InfoFOR FURTHER INFORMATION CONTACT:
David Alterman, Center for Veterinary Medicine (HFV-212), Food and Drug Administration, 7519 Standish Pl., Rockville, MD 20855, 240-453-6843, david.alterman@fda.hhs.gov.
End Further Info End Preamble Start Supplemental InformationSUPPLEMENTARY INFORMATION:
Argent Laboratories, 8702 152d Ave. NE., Redmond, WA 98052 has requested that FDA withdraw approval of the following two NADAs because the products are no longer manufactured or marketed: NADA 042-427 for FINQUEL (tricaine methanesulfonate) and NADA 140-831 for PARACIDE-F (formalin).
Therefore, under authority delegated to the Commissioner of Food and Drugs and redelegated to the Center for Veterinary Medicine, and in accordance with § 514.116 Notice of withdrawal of approval of application (21 CFR 514.116), notice is given that approval of NADAs 042-427 and 140-831, and all supplements and amendments thereto, is hereby withdrawn.
Elsewhere in this issue of the Federal Register, FDA is amending the animal drug regulations to reflect the voluntary withdrawal of approval of these applications.
Start SignatureStart Printed Page 2787End Signature End Supplemental InformationDated: January 9, 2014.
Bernadette Dunham,
Director, Center for Veterinary Medicine.
[FR Doc. 2014-00722 Filed 1-15-14; 8:45 am]
BILLING CODE 4160-01-P
Document Information
- Effective Date:
- 1/27/2014
- Published:
- 01/16/2014
- Department:
- Food and Drug Administration
- Entry Type:
- Rule
- Action:
- Notification of withdrawal.
- Document Number:
- 2014-00722
- Dates:
- Withdrawal of approval is effective January 27, 2014.
- Pages:
- 2786-2787 (2 pages)
- Docket Numbers:
- Docket No. FDA-2013-N-0002
- PDF File:
- 2014-00722.pdf
- Supporting Documents:
- » FREEDOM OF INFORMATION SUMMARY NADA 130-185 AMPROL 25% and FLAVOMYCIN Amprolium and Bambermycins
- » FREEDOM OF INFORMATION SUMMARY Application Number 141-422 PACCAL VET-CA1 Paclitaxel for injection Powder for Injection Dog
- » FREEDOM OF INFORMATION SUMMARY NADA141-420 TILDREN tiludronate disodium Powder for injection Horse
- » FREEDOM OF INFORMATION SUMMARY NADA 141-361 PULMOTIL AC Tilmicosin Phosphate Aqueous Concentrate Swine
- » FREEDOM OF INFORMATION SUMMARY NADA 141-246 AQUAFLOR Florfenicol
- » Freedom of Information Summary NADA 141-288 EXCENEL RTU EZ Ceftiofur Hydrochloride
- » Freedom of Information Summary NADA 095-735 RUMENSIN 90 Monensin
- » Freedom of Information Summary NADA 141-406 NEXGARD Afoxolaner Chewable Tablet
- » Freedom of Information Summary ANADA 200-548 ACTOGAIN 45 Ractopamine Hydrochloride Cattle fed in confinement for slaughter
- » Freedom of Information Summary ANADA 200-542 ENGAIN 9 and ENGAIN 5 Ractopamine Hydrochloride Finishing Swine
- CFR: (2)
- 21 CFR 510
- 21 CFR 529